45 withdrawn. 45 Phase 2, 6 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Withdrawn 45 |
| Phase 1 | 6 | Withdrawn 6 |
| Phase 3 | 5 | Withdrawn 5 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Montelukast Oral Granules - Asthma; Status, Asthma in Children | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2025-09-01 | 2024-11-18 | |
| Terbutaline Sulfate in Adults With Asthma Terbutaline - Asthma | Phase 2 / Phase 3 | Withdrawn | Kanecia Obie Zimmerman | 2023-07-07 | 2026-01-22 | |
| 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study Hyperpolarized Xe129 - Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis | Phase 2 | Withdrawn | University of Kansas Medical Center | 2022-05-01 | 2022-09-10 | |
| Evaluating Effects of Curcumin in Moderate to Severe Asthmatics Curcumin, Placebo - Asthma | Phase 2 | Withdrawn | Loma Linda University | 2021-09-01 | 2021-11-17 | |
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2020-09-01 | 2021-05-14 | |
| A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen AZD8154 nebulizer suspension, 20 mg/mL, Placebo - Asthma | Phase 2 | Withdrawn | AstraZeneca | 2020-02-06 | 2020-11-03 | |
| Anakinra as a Rescue Treatment for Allergic Inflammation Anakinra, Preservative-free 0.9% sodium chloride (Placebo), House dust mite allergen - Asthma, Allergic | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-12-16 | 2022-06-08 | |
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. QAW039 - Asthma, Asthma, Bronchial | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-10-15 | 2020-05-14 | |
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-08-09 | 2021-05-07 | |
| Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis CPM, Placebo - Allergic Rhinitis, Nasal Congestion | Phase 2 / Phase 3 | Withdrawn | Larkin Community Hospital | 2019-07-30 | 2023-10-16 | |
| A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma GSK2245035, Placebo, FP-DPI - Asthma | Phase 2 | Withdrawn | GlaxoSmithKline | 2019-01-21 | 2018-10-16 | |
| A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma Sirukumab, Placebo, Rescue medication - Asthma | Phase 2 | Withdrawn | GlaxoSmithKline | 2016-09-23 | 2018-08-31 | |
| CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids CYT003, Placebo - Asthma | Phase 2 | Withdrawn | Cytos Biotechnology AG | 2014-05-01 | 2014-05-14 | |
| Trial of Simvastatin for the Treatment of Severe Asthma Simvastatin, Placebo - Severe Asthma | Phase 2 | Withdrawn | University of California, Davis | 2013-12-01 | 2017-09-26 | |
| Treating Wheezing in Children With Hypertonic Saline (TWICS) hypertonic saline, saline - Wheeze | Phase 2 | Withdrawn | Dr. Michael Flavin | 2013-10-01 | 2015-11-13 | |
| A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture QAB149 75 mg Concept 1, QAB149 75 mg Epic Test Fixture, Placebo Concept 1 - Asthma | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2013-08-01 | 2017-04-20 | |
| Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol - Allergic Rhinitis | Phase 1 / Phase 2 | Withdrawn | Bryan Martin, DO | 2013-03-01 | 2021-10-28 | |
| Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) MF/F Metered Dose Inhaler (MDI) 25/5 mcg, MF/F MDI 50/5 mcg, MF/F MDI 100/5 mcg - Asthma | Phase 2 | Withdrawn | Organon and Co | 2013-01-01 | 2022-02-16 | |
| Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma albuterol sufate DPI (TBS-7) dose 1, albuterol sufate DPI (TBS-7) dose 2, albuterol sufate DPI (TBS-7) dose 3 - Asthma | Phase 2 | Withdrawn | Acerus Pharmaceuticals Corporation | 2012-11-01 | 2018-03-13 |
Showing 20 of 45. Sign in to see all of them.
Asthma (41) · Rhinitis, Allergic (4) · Respiratory Sounds (2) · Alveolitis, Extrinsic Allergic (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Dyspnea (1) · Eosinophilia (1) · Hypersensitivity (1) · Idiopathic Pulmonary Fibrosis (1) · Lung Diseases, Obstructive (1) · Nasal Obstruction (1) · Obesity (1) · Respiratory Tract Diseases (1) · Rhinitis (1)
Hypersensitivity, Immediate (45) · Immune System Diseases (45) · Hypersensitivity (44) · Respiratory Tract Diseases (44) · Lung Diseases (42) · Bronchial Diseases (40) · Lung Diseases, Obstructive (40) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Pathological Conditions, Signs and Symptoms (3) · Rhinitis (3) · Signs and Symptoms (3) · Infections (2) · Respiration Disorders (2)
Antigens, Dermatophagoides (3) · Interleukin 1 Receptor Antagonist Protein (3) · Sodium Chloride (3) · montelukast (3) · Albuterol (2) · Allergens (2) · Receptors, Interleukin-6 (2) · 2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide (1) · 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole (1) · Adalimumab (1) · Aging (1) · Beclomethasone (1) · CXA-10 (1) · CYT003-QbG10 (1) · Chlorpheniramine (1)
GlaxoSmithKline (4) · Boehringer Ingelheim (3) · University of North Carolina, Chapel Hill (3) · Novartis Pharmaceuticals (2) · University of Chicago (2) · Abbott (1) · Acerus Pharmaceuticals Corporation (1) · Antigen Laboratories, Inc. (1) · AstraZeneca (1) · Boston Children's Hospital (1) · Bryan Martin, DO (1) · Centocor, Inc. (1) · Cytos Biotechnology AG (1) · Dr. Michael Flavin (1) · Florida Atlantic University (1)
United States (16) · Canada (1) · France (1) · Germany (1) · Spain (1) · United Kingdom (1)
Michelle Hernandez, MD (2) · Beverly Paperiello (1) · Blanca Camoretti-Mercado, Ph.D. (1) · Bryan Martin, DO (1) · Donald H Arnold, MD, MPH (1) · James X Hartmann, PhD (1) · Jason Lang, MD (1) · Jerry Krishnan, MD, PhD (1) · Keith Cross, MD (1) · Laren Tan, MD (1)
R01HL135235 (3), 2009 (2), 2008 (1), UL1RR024999 (1)